NR3C2 and cancer: The MR-targeted reprogramming of TAMs, using the synthetic 10-mer RP-182, has shown efficacy in several murine cancer models [197], thus demonstrating the potential for targeting TAM-expressed MR in the context of HCC and the possibilities for future studies.